Methods for using death receptor ligands, such as Apo-2 ligand/TRAIL polypeptides or death receptor antibodies, and EGFR inhibitors to treat pathological conditions such as cancer are provided. Embodiments of the invention include methods of using Apo2L/TRAIL or death receptor antibodies such as DR5 antibodies and DR4 antibodies in combination with EGFR inhibitors, such as Tarceva™.
提供了使用死亡受体
配体(如Apo-2
配体/
TRAIL
多肽或死亡受体
抗体)和
EGFR
抑制剂治疗癌症等病理条件的方法。发明的实施例包括使用Apo2L/
TRAIL或死亡受体
抗体(如DR5
抗体和DR4
抗体)与
EGFR
抑制剂(如Tarceva™)结合的方法。